Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | P2RX3 | P56373 | 16/20 | 0.48 |
| ▸ | P2RX2 | Q9UBL9 | 16/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12830809 | 0.75 | NR1I2 (0.61) | NR1I2CYP2C9P2RX3P2RX2 | |
| SCHEMBL1495440 | 0.75 | NR1I2 (0.61) | NR1I2CYP2C9P2RX3P2RX2 | |
| SCHEMBL451623 | 0.74 | NR1I2 (0.55) | NR1I2CYP2C9P2RX3P2RX2PPARG | |
| SCHEMBL1495392 | 0.73 | NR1I2 (0.57) | NR1I2CYP2C9P2RX3P2RX2 | |
| SCHEMBL12757538 | 0.73 | NR1I2 (0.57) | NR1I2CYP2C9P2RX3P2RX2 | |
| SCHEMBL1495600 | 0.72 | NR1I2 (0.56) | NR1I2CYP2C9P2RX3P2RX2 | |
| SCHEMBL1495603 | 0.72 | NR1I2 (0.56) | NR1I2CYP2C9P2RX3P2RX2 | |
| SCHEMBL12256367 | 0.72 | NR1I2 (0.56) | NR1I2CYP2C9P2RX3P2RX2 | |
| SCHEMBL452273 | 0.72 | ALPL (0.46) | MAPK1 | |
| SCHEMBL1495399 | 0.71 | NR1I2 (0.56) | NR1I2CYP2C9P2RX3P2RX2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238647-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2016-01-19 | — | — | US | disclosed |
| US-9238647-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2016-01-19 | — | — | US | disclosed |
| EP-2410857-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2014-01-29 | — | — | EP | disclosed |
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | P2RX3, P2RX1, P2RX2 | NR1I2 598/4885CYP2C9 4126/4885P2RX3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.